APA (7th ed.) Citation

Peters, S., & Stenzinger, A. (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of oncology, 30(2), . https://doi.org/10.1093/annonc/mdy553

Chicago Style (17th ed.) Citation

Peters, Solange, and Albrecht Stenzinger. "Position of a Panel of International Lung Cancer Experts on the Approval Decision for Use of Durvalumab in Stage III Non-small-cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)." Annals of Oncology 30, no. 2 (2019). https://doi.org/10.1093/annonc/mdy553.

MLA (9th ed.) Citation

Peters, Solange, and Albrecht Stenzinger. "Position of a Panel of International Lung Cancer Experts on the Approval Decision for Use of Durvalumab in Stage III Non-small-cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)." Annals of Oncology, vol. 30, no. 2, 2019, https://doi.org/10.1093/annonc/mdy553.